The evolution of HIV treatment has improved our understanding and management of complex pharmacological issues that have driven improved outcomes and quality of
life of the HIV-infected patient. These include adherence, long and short-term toxicities, pharmacoenhancement, pharmacogenomics, therapeutic drug monitoring (TDM), differential penetration of drugs into sanctuary sites such as the central nervous system (CNS), genital tract and small bowel and drug-drug and drug-food interactions related to cytochrome P450 drug metabolizing enzymes, UGT1A1 and drug transporters to name a few. There is future promise as an increased understanding of the immunopathogenesis of HIV and global public health initiatives are driving novel treatment approaches with goals to prevent, control and ultimately eradicate HIV.
Introduction: The Evolution of HIV Treatment
In less than 30 regimens consisting of two NRTIs plus a PI or NNRTI were capable of virologic suppression (<400 copies/ml), and widespread uptake quickly led to dramatic reductions in morbidity and mortality in the developed world [2] . The strategy of using two NRTIs plus a potent third agent still forms the cornerstone of current Accepted Article treatment principles, and is now referred to as combination antiretroviral therapy (cART) ( Table 1) .
Fluctuation in HIV treatment guidelines over the last two decades reflect the evolving challenges in this field ( Figure 2 ). In 1998 with new treatment optimism the mantra was "Hit hard, hit early" [3] ( Figure 2 ). However, the challenges of HAART were soon realized: high pill burdens, inconvenient dosing, stringent food requirements, treatment limiting toxicities and numerous drug interactions. Unrealistic levels of adherence (>95%) were required to maintain adequate ART exposure and maintain viral suppression [4, 5] . PIs were limited by unfavourable pharmacokinetic (PK) characteristics including limited oral bioavailability, short half-lives, significant interand intra-patient variability, propensity for drug interactions, risk of resistance, <200/mm3/viral load > 100,000 copies/ml ( Figure 2 ). The quest for new approaches to treatment included a paradigm-shifting large randomised clinical trial known as the
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SMART ("Strategies for management of antiretroviral therapy") study which randomized patients either to continuous therapy or a drug conservation arm with either planned deferral of initial therapy until CD4+ < 250 or CD4+ guided discontinuation of treatment [6] Study results showed without question that those randomized to drug conservation endured significantly more AIDS and collective non-AIDS morbidity and mortality compared to those on continuous therapy, and put to rest the notion of "drug holidays" as a viable solution to pill fatigue and toxicities to rest [6] .
More recent cohort studies have also suggested a potential benefit of earlier therapy on survival [7] and an on-going randomized controlled study, the "START study" is examining the impact of earlier treatment in asymptomatic individuals with CD4+ T cell count > 500/mm 3 on HIV and non-HIV events is expected to completed by 2016 [8] .
Treatment success in experienced populations now approaches that seen in treatment naïve populations and this relates to development of new classes of drugs such as integrase strand transfer inhibitors, 2 nd generation NNRTIs, longer acting PIs with fewer toxicities and heat stable ritonavir.
The realization that there would be no immediate cure for HIV highlighted the need to scale-up preventive approaches. It is estimated that more than 50% of HIV transmission results from the 25% of individuals that are unaware of their HIV status and that > 50% of HIV diagnosed individuals are not engaged in medical care [9] .
The HPTN-052 study was a landmark randomized double blind controlled study that showed a significantly longer time to develop AIDS and tuberculosis events [10] .
This study has been a strong driver of the global homogenization of HIV treatment guidelines supporting earlier and unselective initiation of ART across the DHHS, IAS and WHO guidelines ( Figure 2 ). Early ART approaches in the resource poor settings were also modelled to be cost-effective over the life-time of serodiscordant couples [11] .
The treatment of HIV has presented many pharmacological challenges and triumphs.
This review reflects on these and the future of HIV treatment.
Pharmacological Challenges and Triumphs

Pharmacoenhancement/Pharmacokinetic boosting
Early PIs needed to be dosed three times daily either fasting or with a significant meal and/or liquid intake, amounting to daily pill burdens of up to 22. Even with adherence to these stringent criteria, achievable drug exposures were often perilously close to the minimum concentration required for viral inhibition. Imperfect adherence, malabsorption or undetected drug interactions placed patients at risk for sub-therapeutic exposures and risk of virologic breakthrough and development of Accepted Article resistance. A significant advance in treatment was achieved with the concept of pharmacoenhancement with ritonavir. The demonstration that low dose ritonavir (100-200 mg daily) could be used to increase the systemic bioavailability of the accompanying CYP3A4 substrate PI by increasing total AUC, half-life, and minimum concentrations and decreasing PK variability was a major advance [12] . This allowed simplification to once or twice daily administration and led to improved patient adherence and virologic outcomes, particularly in treatment experienced patients where boosted regimens had the ability to overcome low-level PI resistance [13] [14] [15] [16] .
A new pharmacokinetic enhancer, cobicistat was designed to inhibit the CYP3A enzyme without antiretroviral activity. At a dose of 150 mg it was found to exhibit similar CYP3A4 activity to ritonavir 100 mg. Similar to ritonavir, cobicistat also inhibits CYP2D6 and the transporter p-glycoprotein but not CYP1A2, 2C9 or 2C19.
The integrase inhibitor elvitegravir is a CYP3A4 substrate and is coformulated with cobicistat in combination with tenofovir and FTC to allow once daily dosing as a single pill [17, 18] . Cobicistat has also been shown to be an effective booster of atazanavir, and a co-formulated product with darunavir is currently in development.
Studies have suggested that cobicistat shares gastrotinestinal and metabolic toxicities with ritonavir.
The concept of pharmacokinetic enhancement has also been applied to hepatitis C (HCV) antiviral therapy where ritonavir is being co-administered with ABT-450 and danoprevir in phase 2 and late phase 3 studies to optimize PK and simplify dosing [19, 20] . Drawbacks to the use of pharmacokinetic boosters include increased risk of undesirable interactions with concomitant medications.
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Therapeutic Drug Monitoring (TDM)
Measuring Accepted Article or at high risk for drug interactions including patients with concomitant tuberculosis, opportunistic infections, hepatitis B or C co-infection, children, pregnancy, aging, cancer, organ transplant and suspected nonadherence or virological failure) [26] [27] [28] .
Understanding and avoiding drug-drug and food-drug interactions
Drug interactions continue to be a significant challenge in the management of patients with HIV. In the early days, NRTIs in use were associated with many side effects and overlapping toxicities with drugs used to treat opportunistic infections ( Table 2 ).
With the arrival of PIs and NNRTIs and the advent of pharmacokinetic boosting, drug interactions became more complex due to the numerous effects on CYP450 enzymes and transporters, thus making these antiretrovirals frequent perpetrators and victims of drug-drug interactions (Table 2) .
Older HIV patients have more co-morbidities and are at risk to be on several medications heightening the risk of drug-drug interactions [29, 30] 
Adherence/New Drug Formulations
While taking >80% of medication is considered excellent adherence for most chronic diseases, it became clear in the early days of HAART that >95% to ART was required to reliably achieve virologic suppression [5, 41] The first agent to be approved for treatment of HIV was AZT, which was originally dosed at 200 mg every 4 hours based on its short plasma half-life. However, after realization that intracellular concentrations were more relevant than plasma concentrations for NRTIs, AZT dosing was later modified to 300 mg BID, and most drugs in this class are now dosed once daily. Recent progress in overcoming ART adherence challenges has included development of improved drug formulations which lack food and storage considerations, lower pill burden, and more favorable short and long-term toxicity
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profiles. For instance, development of an enteric-coated didanosine capsule formulation removes the risk for cation/buffer interactions, while extended release formulations for stavudine and nevirapine allow once daily dosing. Fosamprenavir, a pro-drug of amprenavir, is associated with significantly reduced daily pill burden, dosing schedule and pill size compared to its predecessor. More recently, development of a heat-stable version of ritonavir has allowed for increased convenience and patient acceptability. administration of a standard 300 mg dose of tenofovir disoproxil [44] . When singletablet-regimens of elvitegravir, cobicistat, emtricitabine and either tenofovir disoproxil or tenofovir alafenamide were compared in treatment naïve subjects, the TAF treatment arm showed similar rates of viral suppression at week 48 and significantly lower bone mineral density change and lesser increase in serum creatinine compared to the tenofovir disoproxil-containing STR arm [45] .
More recently, interest has focused on strategies of switching virologically suppressed patients to better tolerated or simplified regimens in order to enhance long term adherence and treatment perseverance. Switches from efavirenz or boosted PI-based regimens to rilpivirine-tenofovir-emtricitabine single tablet regimen have led to improvements in toxicities including CNS and fasting lipids, respectively, while maintaining virologic suppression [46, 47] .
Switching from boosted PIs or NNRTIs to an InSTI-based regimen in virologically suppressed patients has been similarly successful [48] [49] [50] . However, as illustrated by
the results of the SWITCHMRK study [46, 51] inclusion of agents with a high barrier to resistance is critical to maintaining continued viral suppression, particularly in patients with pre-existing treatment resistance mutations.
Sanctuary Sites
Increased knowledge regarding the distribution of antiretrovirals into various compartments and sanctuary sites has helped to individualize clinical treatment. In the pre-HAART era, AIDS-associated dementia was a frequent and devastating condition where high dose and poorly tolerated oral or intrathecal AZT was the only available strategy to control HIV replication in the CNS. AIDS-associated dementia has significantly decreased with cART, but there is increasing concern regarding more subtle HIV-associated neurocognitive disorders (HAND), even in patients without detectable HIV in plasma. The development of HAND may be correlated with how efficiently various antiretrovirals penetrate the CNS. Early studies yielded inconsistent data regarding the association between cumulative CNS penetration effectiveness (CPE) scores and neurocognitive outcome [52] . A recent study suggests that this approach may have benefit in protecting against cognitive deterioration [53] .
Further research in this area is needed.
Physiological changes associated with pregnancy may affect PI PK and TDM and/or dose adjustment is recommended in the second or third trimester to ensure therapeutic Notably, the success with the prophylactic therapies is dependent on the degree of adherence to the study regimens. The iPrEx study demonstrated that participants having detectable drug concentrations were strongly associated with a significantly lower risk for HIV-1 acquisition (73% efficacy with ≥ 90% adherence) [55] .
Efficacy results have varied across these PrEP trials and have been significantly lower in those involving women. This also highlights the potential differences in
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antiretroviral PK/PD in the male and female genital tracts alongside the significant influence of therapy adherence.
Localized delivery systems such as intravaginal rings [56, 57] show some promise, however, more insight into pharmacological limitations is needed to develop effective PrEP options.
Pharmacogenomics to identify/minimize toxicity
A hypersensitivity syndrome associated with the NRTI abacavir was first described in the pre-marketing phase of drug development and was characterized by fever, malaise, gastrointestinal symptoms and later rash on first exposure with severe hypotension and shock on rechallenge [58, 59] . The discovery of an association between abacavir hypersensitivity and the HLA class I allele HLA-B*57:01 and its translation into routine HIV clinical practice as a guideline endorsed preventive screening strategy has created a roadmap for pharmacogenomic translation [58, 60] ,Since the introduction of routine HLA-B*57:01 screening prior to abacavir prescription, true immunologically mediated abacavir hypersensitivity has disappeared [61] . Other ART toxicity-pharmacogenomic relationships that have been explored in detail and reproduced amongst different groups include CYP2B6 and UGT1A1 polymorphisms and efavirenz exposure/pharmacokinetics and atazanavir associated unconjugated hyperbilirubinemia respectively.
[62] Some studies have suggested relationships between genetic polymorphisms and discontinuation related to ART related adverse events [63] . One small study successfully dose-reduced efavirenz in patients with the CYP2B6 516 G T polymorphism using adjunctive TDM [64] . The CYP2B6 516 G T polymorphism is particularly prevalent in Black
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African and African American populations (up to 20%) and PK studies have demonstrated higher exposure in these populations [65] .
Future Promises
Throughout the progress of the last three decades the primary goals of ART remain largely unchanged: to suppress HIV viral load, to restore immune function, to preserve future treatment options and to improve quality and quantity of life. Newer considerations have included the control of HIV transmission ("treatment as prevention"), consideration for managing and preventing non-AIDS as well as AIDS morbidity and the ultimate goal of HIV eradication or functional cure.
Emerging data has suggested that treatment as prevention approaches are costeffective [11] however there is a massive demand for scale-up and continued improvements in cost-efficiency will be necessary to achieve broader access to 
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An exciting new pharmacological development has been that of nanotechnology to develop long-acting injections of antiretroviral drugs that could be administered once monthly [69, 70] . Accepted Article free of recrudescent HIV replication off cART [74] . The definition and quantification of HIV eradication has not been precisely defined; however 5 years after cART withdrawal there has been significant waning of HIV specific T-cell responses and no evidence of active HIV replication in this patient [75] . Experimental pharmacological strategies to bring HIV out of latency have been examined in early phase studies in
humans. This has included the use of inhibitors of histone deacetylase (HDAC) such as vorinostat which has shown some promise in increasing cell associated HIV RNA, although cells do not die on reactivation of latent HIV meaning that it is likely that a combination of pharmacological, gene and therapeutic vaccine approaches will be necessary to effect eradication [76, 77] .
Conclusions
HIV treatment has evolved from gruelling regimens with high pill burden, Accepted Article As above + addition of EFV as the third agent 1999
As above with addition of ddI/3TC as NRTI combination 2000
As above but high dose RTV removed as third agent and ddI/3TC removed as NRTI combination 2001
As recommendations which in the developed world represented a change from the initial optimism of "hit hard hit early" in 1998 to the reality of challenging high pill burden combinations. In the developing world the trend has moved upwards largely based on increased availability of ART and HIV care in the developing world. The DHHS guidelines have now moved to an evidence based approach where treatment is recommended in all asymptomatic individuals but with various grades of evidence. The European guidelines have been more conservative awaiting the results of the START study a randomized double blinded study of treatment initiation in treatment naïve asymptomatic HIV-infected individuals with CD4+ T cell count >500 or < 500/mm 3 . Although there are differences between guidelines all agree and recommend earlier ART initiation regardless of CD4+ count in high risk patients groups such as those with co-morbidities such as co-infection with hepatitis B or C, HIV-associated nephropathy, rapid decline in CD4+, pregnancy and in serodiscordant partner situations).
